Empagliflozin+Linagliptin is used to manage:
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Linatab E 5/10mg Tablet, comprising Empagliflozin and Linagliptin, falls under the category of antidiabetic agents. It is primarily prescribed to manage type II diabetes mellitus in adults when conventional methods like diet, exercise, and other medications fail to sufficiently control blood sugar levels. This medication is typically used in conjunction with a proper diet and regular exercise regime to achieve optimal results.
Additionally, Linatab E 5/10mg Tablet may also be employed in the management of heart complications in individuals with both diabetes and heart issues. It's crucial to adhere to proper hygiene practices and foot care routines as recommended by your doctor while undergoing treatment with Linatab E 5/10mg Tablet. Regular monitoring of blood glucose levels, as directed by your healthcare provider, is essential.
Before initiating treatment with Linatab E 5/10mg Tablet, inform your doctor about any existing liver or kidney problems. Additionally, if you have recently experienced severe dehydration due to excessive vomiting or diarrhea, it's important to disclose this to your doctor as a precautionary measure.
Notably, Linatab E 5/10mg Tablet is not suitable for patients with Type I diabetes, alcoholism, or diabetic ketoacidosis.
It's advisable to avoid alcohol consumption while taking Linatab E 5/10mg Tablet to minimize the risk of potential unwanted side effects.
Avoid using Linatab E 5/10mg Tablet during pregnancy unless specifically recommended by your doctor due to uncertainty about its effects on the unborn baby.
Consult your doctor before using Linatab E 5/10mg Tablet while breastfeeding as it is not known whether the medication passes through breast milk.
While Linatab E 5/10mg Tablet is not expected to affect your ability to drive or operate heavy machinery, refrain from doing so if you experience any side effects that impair your alertness or coordination.
Use Linatab E 5/10mg Tablet with caution in patients with serious kidney problems. Consult your doctor before starting the medication if you have kidney issues.
Linatab E 5/10mg Tablet is contraindicated in patients with severe liver problems. Avoid using it if you have such conditions and consult your doctor for alternative treatment options.
Empagliflozin and linagliptin both act through different mechanisms to improve glycemic control in patients with type 2 diabetes mellitus:
Empagliflozin inhibits the sodium-glucose co-transporter 2 (SGLT2) in the kidneys. SGLT2 is responsible for reabsorbing glucose from the glomerular filtrate back into the bloodstream. By inhibiting SGLT2, empagliflozin reduces the reabsorption of filtered glucose by the kidneys, thereby increasing the amount of glucose excreted in the urine. This leads to a decrease in blood glucose levels.
Linagliptin is an inhibitor of dipeptidyl peptidase-4 (DPP-4), an enzyme that degrades incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, linagliptin increases the concentration of active incretin hormones, which stimulate the release of insulin from pancreatic beta cells in a glucose-dependent manner. Additionally, GLP-1 inhibits glucagon secretion from pancreatic alpha cells, thereby reducing hepatic glucose output.
The recommended dose of Linagliptin is 5mg once daily. When adding Linagliptin to metformin, the dose of metformin should be maintained, and Linagliptin should be administered concurrently. In combination with a sulphonylurea or insulin, a lower dose of the sulphonylurea or insulin may be considered to mitigate the risk of hypoglycemia.
For patients with renal impairment, no dose adjustment for Linagliptin is necessary. Similarly, pharmacokinetic studies suggest that no dose adjustment is required for patients with hepatic impairment, although clinical experience in this population is limited. No dose adjustment is necessary based solely on age, but caution should be exercised when treating elderly patients, particularly those over 80 years old.
The safety and efficacy of Linagliptin in children and adolescents have not been established yet. Linagliptin can be taken with or without a meal at any time of the day. If a dose is missed, it should be taken as soon as remembered, but a double dose should not be taken on the same day.
In controlled clinical trials involving healthy subjects, single doses of up to 600 mg of Linagliptin were generally well tolerated. However, there is no experience with doses above 600 mg in humans. In the event of an overdose, standard supportive measures should be employed. These may include removing unabsorbed material from the gastrointestinal tract, clinical monitoring, and implementing appropriate clinical interventions if necessary.
Hypersensitivity to the active substance or any of the excipients.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.